Literature DB >> 19327032

APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Susan Bookheimer1, Alison Burggren.   

Abstract

Many years before receiving a clinical diagnosis of Alzheimer's disease (AD), patients experience evidence of cognitive decline. Recent studies using a variety of brain imaging technologies have detected subtle changes in brain structure and function in normal adults with a genetic risk for AD; these brain changes have similar pathological features as AD, and some appear to be predictive of future cognitive decline. This review examines the most recent data on brain changes in genetic risk for AD and discusses the benefits and potential risks of detecting individuals at risk.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19327032      PMCID： PMC3118550          DOI： 10.1146/annurev.clinpsy.032408.153625

Source DB:  PubMed          Journal:  Annu Rev Clin Psychol        ISSN： 1548-5943            Impact factor:   18.561


  114 in total

1.  Impact of rivastigmine use on the risk of nursing home placement in a US sample.

Authors:  Kathleen M Beusterien; Simu K Thomas; Douglas Gause; Miriam Kimel; Stephen Arcona; Dario Mirski
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

2.  Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.

Authors:  K Juottonen; M Lehtovirta; S Helisalmi; P J Riekkinen; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

3.  Dementia patient suffering and caregiver depression.

Authors:  Richard Schulz; Kathleen A McGinnis; Song Zhang; Lynn M Martire; Randy S Hebert; Scott R Beach; Bozena Zdaniuk; Sara J Czaja; Steven H Belle
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Apr-Jun       Impact factor: 2.703

4.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

5.  Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele.

Authors:  R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

6.  Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.

Authors:  William E Klunk; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Brian J Lopresti; Scott K Ziolko; Wenzhu Bi; Jessica A Hoge; Ann D Cohen; Milos D Ikonomovic; Judith A Saxton; Beth E Snitz; Daniel A Pollen; Majaz Moonis; Carol F Lippa; Joan M Swearer; Keith A Johnson; Dorene M Rentz; Alan J Fischman; Howard J Aizenstein; Steven T DeKosky
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

Review 7.  An active and socially integrated lifestyle in late life might protect against dementia.

Authors:  Laura Fratiglioni; Stephanie Paillard-Borg; Bengt Winblad
Journal:  Lancet Neurol       Date:  2004-06       Impact factor: 44.182

8.  Brain imaging evidence of preclinical Alzheimer's disease in normal aging.

Authors:  William Jagust; Amy Gitcho; Felice Sun; Beth Kuczynski; Dan Mungas; Mary Haan
Journal:  Ann Neurol       Date:  2006-04       Impact factor: 10.422

9.  Behavioral and psychological symptoms in the preclinical stage of Alzheimer's disease.

Authors:  Leszek Bidzan; Maria Pachalska; Bozena Grochmal-Bach; Mariola Bidzan; Anna Cieslukowska; Anna Pufal
Journal:  Med Sci Monit       Date:  2008-09

10.  The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.

Authors:  Kenneth Rockwood; Sherri Fay; Mary Gorman; Daniel Carver; Janice E Graham
Journal:  BMC Neurol       Date:  2007-08-30       Impact factor: 2.474
View more
  48 in total

1.  Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant.

Authors:  Susanne Erk; Andreas Meyer-Lindenberg; Carola Opitz von Boberfeld; Christine Esslinger; Knut Schnell; Peter Kirsch; Manuel Mattheisen; Thomas W Mühleisen; Sven Cichon; Stephanie H Witt; Marcella Rietschel; Markus M Nöthen; Henrik Walter
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

2.  Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old.

Authors:  Jonas Mengel-From; Kaare Christensen; Matt McGue; Lene Christiansen
Journal:  Neurobiol Aging       Date:  2010-08-23       Impact factor: 4.673

Review 3.  Imaging genomics.

Authors:  Paul M Thompson; Nicholas G Martin; Margaret J Wright
Journal:  Curr Opin Neurol       Date:  2010-08       Impact factor: 5.710

4.  Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer's disease.

Authors:  N Maritza Dowling; Bruce Hermann; Asenath La Rue; Mark A Sager
Journal:  Neuropsychology       Date:  2010-11       Impact factor: 3.295

5.  Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.

Authors:  Brenna C McDonald; Susan K Conroy; Dori J Smith; John D West; Andrew J Saykin
Journal:  Brain Behav Immun       Date:  2012-05-18       Impact factor: 7.217

6.  A combined effect of two Alzheimer's risk genes on medial temporal activity during executive attention in young adults.

Authors:  Adam E Green; Jeremy R Gray; Colin G Deyoung; Timothy R Mhyre; Robert Padilla; Amanda M Dibattista; G William Rebeck
Journal:  Neuropsychologia       Date:  2014-01-02       Impact factor: 3.139

7.  APOE epsilon4 and the cognitive genetics of multiple sclerosis.

Authors:  O Ghaffar; M Reis; N Pennell; P O'Connor; A Feinstein
Journal:  Neurology       Date:  2010-05-18       Impact factor: 9.910

Review 8.  Sex differences in cognitive impairment and Alzheimer's disease.

Authors:  Rena Li; Meharvan Singh
Journal:  Front Neuroendocrinol       Date:  2014-01-13       Impact factor: 8.606

9.  Reduced hippocampal CA2, CA3, and dentate gyrus activity in asymptomatic people at genetic risk for Alzheimer's disease.

Authors:  Nanthia A Suthana; Allison Krupa; Markus Donix; Alison Burggren; Arne D Ekstrom; Michael Jones; Linda M Ercoli; Karen J Miller; Prabha Siddarth; Gary W Small; Susan Y Bookheimer
Journal:  Neuroimage       Date:  2009-12-18       Impact factor: 6.556

10.  Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife.

Authors:  Séverine Sabia; Mika Kivimaki; Meena Kumari; Martin J Shipley; Archana Singh-Manoux
Journal:  Mol Neurodegener       Date:  2010-06-01       Impact factor: 14.195
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.